Compile Data Set for Download or QSAR
Report error Found 43 Enz. Inhib. hit(s) with all data for entry = 831
TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293963(US10106552, Compound 38)
Affinity DataIC50: 300nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293965(US10106552, Compound 40)
Affinity DataIC50: 400nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293953(US10106552, Compound 28)
Affinity DataIC50: 400nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293961(US10106552, Compound 36)
Affinity DataIC50: 400nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293960(US10106552, Compound 35)
Affinity DataIC50: 400nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293966(US10106552, Compound 41)
Affinity DataIC50: 500nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293954(US10106552, Compound 29)
Affinity DataIC50: 700nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293950(US10106552, Compound 25)
Affinity DataIC50: 800nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293959(US10106552, Compound 34)
Affinity DataIC50: 800nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293943(US10106552, Compound 18)
Affinity DataIC50: 900nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293962(US10106552, Compound 37)
Affinity DataIC50: 900nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293968(US10106552, Compound 43)
Affinity DataIC50: 900nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293935(US10106552, Compound 10)
Affinity DataIC50: 1.00E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293951(US10106552, Compound 26)
Affinity DataIC50: 1.00E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293958(US10106552, Compound 33)
Affinity DataIC50: 1.10E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293944(US10106552, Compound 19)
Affinity DataIC50: 1.10E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293927(US10106552, Compound 2)
Affinity DataIC50: 1.10E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293942(US10106552, Compound 17)
Affinity DataIC50: 1.10E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293931(US10106552, Compound 6)
Affinity DataIC50: 1.20E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293949(US10106552, Compound 24)
Affinity DataIC50: 1.40E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293964(US10106552, Compound 39)
Affinity DataIC50: 1.40E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293952(US10106552, Compound 27)
Affinity DataIC50: 1.50E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293932(US10106552, Compound 7)
Affinity DataIC50: 1.60E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293946(US10106552, Compound 21)
Affinity DataIC50: 2.00E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293948(US10106552, Compound 23)
Affinity DataIC50: 2.00E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293945(US10106552, Compound 20)
Affinity DataIC50: 2.20E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293934(US10106552, Compound 9)
Affinity DataIC50: 2.40E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293940(US10106552, Compound 15)
Affinity DataIC50: 2.50E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293926(US10106552, Compound 1)
Affinity DataIC50: 2.70E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293967(US10106552, Compound 42)
Affinity DataIC50: 3.10E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293955(US10106552, Compound 30)
Affinity DataIC50: 3.40E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293956(US10106552, Compound 31)
Affinity DataIC50: 3.50E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293957(US10106552, Compound 32)
Affinity DataIC50: 3.80E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293941(US10106552, Compound 16)
Affinity DataIC50: 4.60E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293933(US10106552, Compound 8)
Affinity DataIC50: 4.70E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293937(US10106552, Compound 12)
Affinity DataIC50: 5.00E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293930(US10106552, Compound 5)
Affinity DataIC50: 6.00E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293947(US10106552, Compound 22)
Affinity DataIC50: 6.00E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293936(US10106552, Compound 11)
Affinity DataIC50: 2.30E+4nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293938(US10106552, Compound 13)
Affinity DataIC50: 3.10E+4nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293939(US10106552, Compound 14)
Affinity DataIC50: 5.02E+6nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293929(US10106552, Compound 4)
Affinity DataIC50: 1.00E+7nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293928(US10106552, Compound 3)
Affinity DataIC50: 1.00E+7nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent